This study presented a complete downstream process for inactivated
cell culture-derived influenza vaccine. This downstream
process resulted in high HA recovery and substantial reduction of
the impurities. The final product meets the impurity limit required
by regulatory authorities. All operation is easy to scale up and is
a potential candidate downstream process for cell culture-derived
influenza vaccine production.